Document Detail


Milrinone for long-term therapy of severe heart failure: clinical experience with special reference to maximal exercise tolerance.
MedLine Citation:
PMID:  3510777     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Thirty-seven patients with severe chronic heart failure were entered into an open-ended trial with milrinone at an initial daily dose ranging form 20 to 30 mg. Mean duration of treatment was 48 weeks and ranged from 1 to 134 weeks. Twenty-five patients (67%) reported a substantial improvement in well-being with less dyspnea or fatigue, but this was not associated with a significant increase in maximal oxygen uptake: 10.2 +/- 2.9 vs 10.7 +/- 2.4 ml/kg/min (NS). At intervals ranging from 6 to 54 weeks, they experienced a recurrence of symptoms that was partially reversed by increasing the dose of milrinone to a maximum of 50 mg/day. In 15 patients whose symptoms could not be controlled by milrinone alone, captopril was added. The combination of captopril and milrinone was well tolerated and produced a symptomatic improvement in 10 of the 15 patients (67%). Maximal oxygen uptake, however, was not significantly increased by addition of captopril to milrinone: 10.6 +/- 2.7 vs 11.6 +/- 3.3 ml/kg/min. Twenty-four patients died: 12 of sudden death and 12 of gradual worsening of heart failure. During prolonged administration of milrinone, no patient experienced overt clinical adverse reactions directly attributable to the drug. Left ventricular end-diastolic dimension increased from 3.6 +/- 0.7 to 4.1 +/- 0.9 cm/m2 (p less than .05) after a mean duration of 50 weeks of milrinone therapy. Accordingly, long-term therapy with milrinone appears to improve functional status without eliciting overt clinical adverse reactions. However, the possibility that milrinone might have contributed to the high mortality noted during this therapeutic trial cannot be excluded.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
T H LeJemtel; D Gumbardo; B Chadwick; H I Rutman; E H Sonnenblick
Related Documents :
6750167 - Comparison of propranolol and hydrochlorothiazide for the initial treatment of hyperten...
18410867 - Preoperative beta-blocker use: impact of national guidelines on clinical practice.
7829787 - Intermittent transdermal nitrates do not improve ischemia in patients taking beta-block...
14627967 - Routine beta-blockade in vascular surgery.
19359917 - Characterization of persistent hyperglycemia: what does it mean postinjury?
23552607 - Comparison of preferences between onabotulinumtoxina (botox) and incobotulinumtoxina (x...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Circulation     Volume:  73     ISSN:  0009-7322     ISO Abbreviation:  Circulation     Publication Date:  1986 Mar 
Date Detail:
Created Date:  1986-03-21     Completed Date:  1986-03-21     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  III213-8     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Captopril / therapeutic use
Cardiotonic Agents / pharmacology,  therapeutic use*
Chronic Disease
Clinical Trials as Topic
Drug Therapy, Combination
Heart Failure / drug therapy*,  mortality
Humans
Middle Aged
Milrinone
Oxygen Consumption / drug effects
Physical Exertion / drug effects*
Pyridones / pharmacology,  therapeutic use*
Time Factors
Chemical
Reg. No./Substance:
0/Cardiotonic Agents; 0/Pyridones; 62571-86-2/Captopril; 78415-72-2/Milrinone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Assessment of long-term therapy with milrinone and the effects of milrinone withdrawal.
Next Document:  Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (M...